Role of serum and induced sputum surfactant protein D in predicting the response to treatment in chronic obstructive pulmonary disease

Liu,Wei; Ju,Chun‑Rong; Chen,Rong‑Chang; Liu,Zhi‑Guang

doi:10.3892/etm.2014.1865

Role of serum and induced sputum surfactant protein D in predicting the response to treatment in chronic obstructive pulmonary disease

Authors:
- Wei Liu
- Chun‑Rong Ju
- Rong‑Chang Chen
- Zhi‑Guang Liu
View Affiliations

Affiliations: State Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong 510120, P.R. China, Department of Respiratory Medicine, Hunan Provincial People's Hospital, The First Affiliated Hospital of Hunan Normal University, Changsha, Hunan 410005, P.R. China
Published online on: July 29, 2014 https://doi.org/10.3892/etm.2014.1865
Pages: 1313-1317

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

This study was designed to determine the expression of serum and sputum surfactant protein D (SP‑D) in chronic obstructive pulmonary disease (COPD) and its association with treatment response. Sixty‑five treatment‑naive patients with COPD and 26 normal control subjects were recruited in the study. The concentrations of serum and sputum SP‑D were measured, and the associations of SP‑D with pulmonary function and the modified Medical Research Council dyspnea scale (mMRC) and the St. George's Respiratory Questionnaire (SGRQ) scores before and after three months of treatment with an inhaled corticosteroid and a long‑acting β2‑agonist were analyzed. The concentrations of serum and sputum SP‑D in the COPD group (45.46±37.78 and 173.23±186.93 ng/ml, respectively) were significantly higher than those of the normal control group (31.68±12.04 and 89.59±70.29 ng/ml, respectively). After three months of treatment, serum SP‑D levels were reduced to 30.7±13.9 ng/ml and were significantly lower than the baseline levels (t=2.217, P=0.031). However, no significant reduction in sputum SP‑D levels was observed following the treatment (P>0.05). A significant association between baseline sputum SP‑D and change in SGRQ activity scores (r=‑0.652, P=0.012) was observed; however no association was established with the changes in other clinical profiles following the treatment (P>0.05). This result suggested that an increased baseline sputum SP‑D may be a weak predictive indicator of response to treatment with inhaled corticosteroids and long‑acting β2‑agonists in patients with COPD.

View Figures

View References

1	Vestbo J, Hurd SS, Agustí AG, et al: Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 187:347–365. 2013. View Article : Google Scholar : PubMed/NCBI
2	Wulf-Johansson H, Thinggaard M, Tan Q, et al: Circulating surfactant protein D is associated to mortality in elderly women: a twin study. Immunobiology. 218:712–717. 2013. View Article : Google Scholar : PubMed/NCBI
3	Sin DD, Man SF, Marciniuk DD, et al; ABC (Advair, Biomarkers in COPD) Investigators. The effects of fluticasone with or without salmeterol on systemic biomarkers of inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 177:1207–1214. 2008. View Article : Google Scholar : PubMed/NCBI
4	Shakoori TA, Sin DD, Ghafoor F, Bashir S and Bokhari SN: Serum surfactant protein D during acute exacerbations of chronic obstructive pulmonary disease. Dis Markers. 27:287–294. 2009. View Article : Google Scholar : PubMed/NCBI
5	Ju CR, Liu W and Chen RC: Serum surfactant protein D: biomarker of chronic obstructive pulmonary disease. Dis Markers. 32:281–287. 2012. View Article : Google Scholar : PubMed/NCBI
6	Sin DD, Leung R, Gan WQ and Man SP: Circulating surfactant protein D as a potential lung-specific biomarker of health outcomes in COPD: a pilot study. BMC Pulm Med. 7:132007. View Article : Google Scholar : PubMed/NCBI
7	García-Laorden MI, Rodríguez de Castro F, Solé-Violán J, et al: Influence of genetic variability at the surfactant proteins A and D in community-acquired pneumonia: a prospective, observational, genetic study. Crit Care. 15:R572011.PubMed/NCBI
8	Boonarkart CH, Suptawiwat O, Uiprasertkul M, et al: A reduced expression of surfactant protein D in the lungs of fatal influenza H1N1 cases in 2009. Acta Virol. 56:253–255. 2012. View Article : Google Scholar : PubMed/NCBI
9	Atochina-Vasserman EN, Winkler C, Abramova H, et al: Segmental allergen challenge alters multimeric structure and function of surfactant protein D in humans. Am J Respir Crit Care Med. 183:856–864. 2011. View Article : Google Scholar : PubMed/NCBI
10	King BA and Kingma PS: Surfactant protein D deficiency increases lung injury during endotoxemia. Am J Respir Cell Mol Biol. 44:709–715. 2011. View Article : Google Scholar : PubMed/NCBI
11	Ware LB, Koyama T, Billheimer DD, et al; NHLBI ARDS Clinical Trials Network. Prognostic and pathogenetic value of combining clinical and biochemical indices in patients with acute lung injury. Chest. 137:288–296. 2010. View Article : Google Scholar : PubMed/NCBI
12	Sin DD, Man SF, McWilliams A and Lam S: Surfactant protein D and bronchial dysplasia in smokers at high risk of lung cancer. Chest. 134:582–588. 2008. View Article : Google Scholar : PubMed/NCBI
13	Madan T, Reid KB, Clark H, et al: Susceptibility of mice genetically deficient in SP-A or SP-D gene to invasive pulmonary aspergillosis. Mol Immunol. 47:1923–1930. 2010. View Article : Google Scholar : PubMed/NCBI
14	Ichiyasu H, Ichikado K, Yamashita A, et al: Pneumocyte biomarkers KL-6 and surfactant protein D reflect the distinct findings of high-resolution computed tomography in nonspecific interstitial pneumonia. Respiration. 83:190–197. 2012. View Article : Google Scholar
15	Lomas DA, Silverman EK, Edwards LD, et al; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints study investigators. Serum surfactant protein D is steroid sensitive and associated with exacerbations of COPD. Eur Respir J. 34:95–102. 2009. View Article : Google Scholar : PubMed/NCBI
16	Vestbo J, Edwards LD, Scanlon PD, et al; ECLIPSE Investigators. Changes in forced expiratory volume in 1 second over time in COPD. N Engl J Med. 365:1184–1192. 2011.PubMed/NCBI
17	Engström G, Lindberg C, Gerhardsson de Verdier M, et al: Blood biomarkers and measures of pulmonary function - a study from the Swedish twin registry. Respir Med. 106:1250–1257. 2012.PubMed/NCBI
18	Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. http://www.goldcopd.org/uri. Accessed December 31, 2011
19	Miller MR, Hankinson J, Brusasco V, et al; ATS/ERS Task Force. Standardisation of spirometry. Eur Respir J. 26:319–338. 2005. View Article : Google Scholar : PubMed/NCBI
20	Beeh KM, Beier J, Kornmann O and Buhl R: Sputum matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-1, and their molar ratio in patients with chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis and healthy subjects. Respir Med. 97:634–639. 2003. View Article : Google Scholar
21	Sin DD and Vestbo J: Biomarkers in chronic obstructive pulmonary disease. Proc Am Thorac Soc. 6:543–545. 2009. View Article : Google Scholar : PubMed/NCBI
22	Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 69:89–95. 2001. View Article : Google Scholar : PubMed/NCBI
23	Koutsokera A, Stolz D, Loukides S and Kostikas K: Systemic biomarkers in exacerbations of COPD: the evolving clinical challenge. Chest. 141:396–405. 2012. View Article : Google Scholar : PubMed/NCBI
24	van Durme YM, Verhamme KM, Aarnoudse AJ, et al: C-reactive protein levels, haplotypes, and the risk of incident chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 179:375–382. 2009.PubMed/NCBI
25	Hartl D and Griese M: Surfactant protein D in human lung diseases. Eur J Clin Invest. 36:423–435. 2006. View Article : Google Scholar : PubMed/NCBI
26	Dickens JA, Miller BE, Edwards LD, et al; Evaluation of COPD Longitudinally to Identify Surrogate Endpoints (ECLIPSE) study investigators. COPD association and repeatability of blood biomarkers in the ECLIPSE cohort. Respir Res. 12:1462011. View Article : Google Scholar : PubMed/NCBI
27	Hoegh SV, Sorensen GL, Tornoe I, et al: Long-term stability and circadian variation in circulating levels of surfactant protein D. Immunobiology. 215:314–320. 2010. View Article : Google Scholar : PubMed/NCBI
28	Wang IM, Stepaniants S, Boie Y, et al: Gene expression profiling in patients with chronic obstructive pulmonary disease and lung cancer. Am J Respir Crit Care Med. 177:402–411. 2008. View Article : Google Scholar : PubMed/NCBI
29	Foreman MG, Kong X, DeMeo DL, et al: Polymorphisms in surfactant protein-D are associated with chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol. 44:316–322. 2011. View Article : Google Scholar : PubMed/NCBI
30	The Chronic Obstructive Pulmonary Disease group of Chinese Thoracic Society. The diagnosis and treatment guideline of chronic obstructive pulmonary disease. Zhonghua Jie He He Hu Xi Za Zhi. 30:8–17. 2007.(In Chinese).
31	Braido F, Bagnasco D, Scichilone N, et al: Biomarkers in obstructive respiratory diseases: an update. Panminerva Med. 54:119–127. 2012.PubMed/NCBI
32	Celli BR, Locantore N, Yates J, et al; ECLIPSE Investigators. Inflammatory biomarkers improve clinical prediction of mortality in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 185:1065–1072. 2012. View Article : Google Scholar : PubMed/NCBI